Serina Therapeutics Bilan de santé
Santé financière contrôle des critères 0/6
Serina Therapeutics has a total shareholder equity of $-16.4M and total debt of $11.1M, which brings its debt-to-equity ratio to -67.9%. Its total assets and total liabilities are $10.7M and $27.1M respectively.
Informations clés
-67.9%
Ratio d'endettement
US$11.14m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$6.06m |
| Fonds propres | -US$16.39m |
| Total du passif | US$27.10m |
| Total des actifs | US$10.71m |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Analyse de la situation financière
Passif à court terme: 2BO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: 2BO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: 2BO has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: 2BO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: 2BO has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: 2BO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 57.3% each year